ATE530650T1 - Hochaffine antagonisten von elr-cxc-chemokinen - Google Patents

Hochaffine antagonisten von elr-cxc-chemokinen

Info

Publication number
ATE530650T1
ATE530650T1 AT07719770T AT07719770T ATE530650T1 AT E530650 T1 ATE530650 T1 AT E530650T1 AT 07719770 T AT07719770 T AT 07719770T AT 07719770 T AT07719770 T AT 07719770T AT E530650 T1 ATE530650 T1 AT E530650T1
Authority
AT
Austria
Prior art keywords
afffine
elr
antagonists
cxc chemokines
cxc
Prior art date
Application number
AT07719770T
Other languages
English (en)
Inventor
John R Gordon
Original Assignee
Univ Saskatchewan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38693498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE530650(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Saskatchewan filed Critical Univ Saskatchewan
Application granted granted Critical
Publication of ATE530650T1 publication Critical patent/ATE530650T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5421—IL-8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT07719770T 2006-05-16 2007-05-16 Hochaffine antagonisten von elr-cxc-chemokinen ATE530650T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80040606P 2006-05-16 2006-05-16
PCT/CA2007/000848 WO2007131352A1 (en) 2006-05-16 2007-05-16 High-affinity antagonists of elr-cxc chemokines

Publications (1)

Publication Number Publication Date
ATE530650T1 true ATE530650T1 (de) 2011-11-15

Family

ID=38693498

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07719770T ATE530650T1 (de) 2006-05-16 2007-05-16 Hochaffine antagonisten von elr-cxc-chemokinen

Country Status (15)

Country Link
US (1) US8039429B2 (de)
EP (1) EP2021475B1 (de)
JP (1) JP5462623B2 (de)
CN (1) CN101484579B (de)
AR (1) AR060960A1 (de)
AT (1) ATE530650T1 (de)
AU (1) AU2007250429A1 (de)
BR (1) BRPI0711589A2 (de)
CA (1) CA2652094A1 (de)
CL (1) CL2007001402A1 (de)
IL (1) IL195309A0 (de)
MX (1) MX2008014656A (de)
NZ (1) NZ573657A (de)
TW (1) TW200813084A (de)
WO (1) WO2007131352A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100530A1 (en) * 2008-02-12 2009-08-20 University Of Saskatchewan Uses of modified elr-cxc chemokine g31p
CN110420316A (zh) * 2013-06-18 2019-11-08 纽约大学 参与金黄色葡萄球菌杀白细胞素的细胞毒性的细胞因素：新型治疗靶点
CN103399151A (zh) * 2013-06-24 2013-11-20 上海交通大学医学院附属瑞金医院 Cxcl8细胞因子检测试剂在制备甲状腺乳头状癌的诊断试剂中的应用
CN104832798A (zh) * 2014-02-10 2015-08-12 欧司朗有限公司 Led照明装置
CA3046489A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP3554541B1 (de) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Behandlung einer erkrankung des gastrointestinaltraktes mit einem chemokin/chemokin-rezeptor-inhibitor
CN109022599A (zh) * 2018-10-08 2018-12-18 河南科技学院 检测奶牛CCL28基因单核苷酸多态性的试剂盒及RFLP方法及相关SNPs
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0804486B1 (de) * 1992-11-27 2008-10-01 Laboratoires Serono SA Chemotaktisches protein für granulozyten
CA2439452C (en) * 2001-03-01 2012-05-15 University Of Saskatchewan Technologies Inc. High-affinity antagonists of elr-cxc chemokines

Also Published As

Publication number Publication date
EP2021475B1 (de) 2011-10-26
CA2652094A1 (en) 2007-11-22
TW200813084A (en) 2008-03-16
NZ573657A (en) 2011-09-30
EP2021475A1 (de) 2009-02-11
WO2007131352A1 (en) 2007-11-22
IL195309A0 (en) 2011-08-01
BRPI0711589A2 (pt) 2011-11-16
EP2021475A4 (de) 2009-12-09
AU2007250429A1 (en) 2007-11-22
AR060960A1 (es) 2008-07-23
CL2007001402A1 (es) 2008-03-14
JP2009542192A (ja) 2009-12-03
CN101484579B (zh) 2012-02-29
US8039429B2 (en) 2011-10-18
US20090270318A1 (en) 2009-10-29
MX2008014656A (es) 2009-01-30
JP5462623B2 (ja) 2014-04-02
CN101484579A (zh) 2009-07-15

Similar Documents

Publication Publication Date Title
HRP20151108T1 (xx) Antagonisti nogo-receptora
EP2004654A4 (de) Kinase-antagonisten
EP2083864A4 (de) Antagonisten von pcsk9
EP2083859A4 (de) Pcsk9-antagonisten
EP2083860A4 (de) Pcsk9-antagonisten
EP2027592A4 (de) Verdampfer
EP2217701A4 (de) Glucagon-antagonisten
DK1720866T3 (da) Fremgangsmåde
DK2018201T3 (da) Forstøver
DK1986650T3 (da) Manipulationssikre doserignsformer
RU2458924C3 (ru) Соединения замещенных диазепанов в качестве антагонистов орексиновых рецепторов
DK1963369T3 (da) Il-21-antagonister
BRPI0817835A2 (pt) Antagonistas cgrp
DE602007013051D1 (de) Sprühvorrichtung
ATE530650T1 (de) Hochaffine antagonisten von elr-cxc-chemokinen
BRPI0718494A2 (pt) Derivado de fenilsulfamoil benzamida como antagonistas de bradicinina
ATE533744T1 (de) N-benzoypyrrolidin-3-ylamine als histamin-3 antagonisten
BRPI0718436A2 (pt) Novos derivados de benzamida como antagonistas da bradicina
ATE512963T1 (de) Heterocyclen als orexinantagonisten
DE602007012260D1 (de) Nitratester von piperidinen
BRPI0908008A2 (pt) Farmacóforo dual - pde4-antagonistas muscarínicos
ATE524972T1 (de) Poly-tlr-antagonist
BRPI0907519A2 (pt) Antagonistas farmacoforos-pde4-muscarínicos duais
SE0601926L (sv) Kokkärl
DE502007004639D1 (de) Sprühdose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties